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Introduction
============

Methotrexate is an effective treatment for malignant as well as several non-malignant inflammatory diseases.[@ref1] It is recommended as a first line disease modifying treatment for rheumatoid arthritis,[@ref2] [@ref3] psoriatic arthritis, and psoriasis,[@ref4] [@ref5] [@ref6] and for both the induction and maintenance of remission in Crohn's disease.[@ref7] Methotrexate may be used as monotherapy or in combination with other drugs, including oral agents and newer biologicals.[@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] In some disorders methotrexate is not only disease altering but also life saving.[@ref8] [@ref9]

Methotrexate has been implicated as a cause of serious lung toxicity.[@ref1] [@ref2] [@ref3] [@ref6] The prevalence of methotrexate related interstitial lung disease remains unknown but has been reported to be as high as 11.6% in rheumatoid arthritis.[@ref10] Studies of methotrexate induced lung disease among rheumatoid arthritis populations are confounded by the propensity to develop pulmonary infections and pulmonary manifestations of rheumatoid arthritis itself, concomitant drug use, and a higher rate of pulmonary fatalities.[@ref11] [@ref12] [@ref13] Distinguishing between rheumatoid arthritis related and methotrexate related interstitial lung disease is difficult if not impossible since the clinical and histological features overlap.[@ref14] [@ref15] [@ref16] Aside from case reports, all previous studies of methotrexate related interstitial lung disease have been in rheumatoid arthritis.

A recent meta-analysis of clinical trials of rheumatoid arthritis reported a small but significant increase in infectious respiratory complications but no increase in non-infectious events among participants treated with methotrexate.[@ref17] Studies of clinical trials among diseases without pulmonary manifestations provide an opportunity to evaluate this problem more clearly.

We performed a meta-analysis of randomised controlled trials of 12 weeks or greater duration to evaluate if methotrexate is associated with an increased risk of lung disease in adults with psoriasis, psoriatic arthritis, and inflammatory bowel disease.

Methods
=======

Data sources and searches
-------------------------

We carried out a systematic literature search with no date limits using PubMed, the Cochrane central register of controlled trials, and Embase. The search was performed to 9 January 2014 (see supplementary file for keywords used in search strategy). We also searched for previously published meta-analyses and systematic literature reviews. The reference lists of relevant articles were also reviewed.

Study selection
---------------

Two authors (CL and RC) independently performed the literature search, with discrepancies resolved by consensus.

The inclusion criteria for study selection were: double blind randomised controlled trials; patients with psoriasis, psoriatic arthritis, or inflammatory bowel disease; studies in English; studies consisting of a minimum of two arms, at least one receiving methotrexate and at least one not receiving methotrexate; studies including only adults (≥18 years); trials of 12 weeks or more duration; studies of 50 patients or more; and studies reporting respiratory side effects for methotrexate and comparator groups separately. In the case of multiple publications of one randomised controlled trial we included the publication most relevant to our inclusion criteria, in terms of detailed reporting of respiratory side effects. If the results of a study were reported at multiple time points, we included the publication of greatest duration provided it remained a double blind randomised controlled trial and fully reported respiratory adverse events. If required we reviewed previous publications of the same trial to fully assess the trial protocol and risk of bias. This approach was taken to avoid including participants more than once in the meta-analysis.

We selected relevant articles using a two step approach. Firstly, we screened the titles and abstracts of identified references to exclude articles that did not deal with the topic of interest. Secondly, we reviewed the full text of relevant articles.

Data extraction and quality assessment
--------------------------------------

For each included study two authors (CL and RC) independently extracted data and resolved discrepancies by discussion. One author (CL) entered the data into a database, and the remaining authors checked these entries.

We extracted several variables: authors, year of publication, population studied, number of patients, mean age and range, sex, disease duration, percentage methotrexate naive, previous immunosuppressive drug use, steroid use at baseline, folic acid or folinic acid usage, study design and duration, comparator drug, and adverse events. Adverse events were extracted as both total respiratory adverse events and individual adverse events in each category reported in any individual trial. The terminology used to describe respiratory adverse events varied widely in the included studies; to overcome the lack of standardisation in terminology used, we classified adverse events into two subgroups: infectious adverse events and non-infectious adverse events.

Data synthesis and analysis
---------------------------

We meta-analysed data using RevMan Version 5.1 software,[@ref18] expressed as relative risk for dichotomous variables. Throughout we used random effects meta-analysis using the Mantel-Haenszel method. Results are expressed as relative risks with 95% confidence intervals.

Assessment of bias
------------------

To assess for trial level risk of bias in included studies we used the criteria described in the Cochrane handbook.[@ref19] Two authors (CL and RC) independently assessed studies for risk of bias. Discrepancies were resolved by discussion and consensus. A risk of bias graph and summary were generated. We generated funnel plots to assess for publication bias.

Sensitivity analysis
--------------------

We performed sensitivity analysis to assess the effect of trial size (\<250 participants versus ≥250 participants), disease (psoriasis, psoriatic arthritis, or inflammatory bowel disease), comparator drug (placebo versus active comparator), folic acid use (documented versus none or unclear use), methotrexate naivety, drop-out rates, and effect of including studies with fewer than 50 patients.

Results
=======

Literature search
-----------------

From the literature search 3188 citations were identified: 2968 from PubMed, 162 from the Cochrane central register of controlled trials, and 58 from Embase. Of the 3188 studies, only seven articles met the predefined inclusion criteria and were included in the meta-analysis (fig 1[](#fig1){ref-type="fig"}).

![**Fig 1** Flow of studies through review](conr023287.f1_default){#fig1}

Study characteristics
---------------------

The seven included studies comprised 1640 patients, 818 of whom received methotrexate and 812 comparator treatments (table 1[](#tbl1){ref-type="table"}). The study durations ranged from 16 to 52 weeks and the number of patients from 76 to 478. The studies reported a total of 946 patient years of exposure. Five studies involved placebo comparators only, one a monoclonal antibody alone, and one placebo and monoclonal antibody comparator groups.[@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26]

###### 

 Characteristics of studies included in meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                Year   Comparator drug      Methotrexate (No)   Comparator (No)   Study duration (weeks)   Age (years)\*   Female (%)   Disease duration, (years)\*   Methotrexate naïve (%)   Methotrexate dose, weekly (median)
  -------------------- ------ -------------------- ------------------- ----------------- ------------------------ --------------- ------------ ----------------------------- ------------------------ ------------------------------------
  Feagan et al^20^     2014   Placebo              63                  63                50                       39              44           10                            NA                       25 mg subcutaneous

  Gottlieb et al^21^   2012   Placebo              239                 239               24                       44              33           17                            83                       15 mg oral

  Kingsley et al^22^   2012   Placebo              109\                112               24                       49              44           1                             100                      15 mg oral

  Reich et al^23^      2011   Briakinumab          163                 154               52                       44              30           19                            100                      25 mg oral

  Saurat et al^24^     2008   Adalimumab/placebo   110                 161               16                       42              34           19                            100                      15 mg oral

  Feagan et al^25^     2000   Placebo              40                  36                40                       33              50           7                             0                        15 mg intramuscular

  Feagan et al^26^     1995   Placebo              94                  47                16                       35              46           8                             NA                       25 mg intramuscular
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA=not available.

\*Age and duration of disease expressed as mean as reported by individual studies.

Findings
--------

Overall, 504 respiratory adverse events were documented (table 2[](#tbl2){ref-type="table"}). Although the I^2^ index was low (0%), the type and number of respiratory adverse events reported varied considerably between the studies so we chose a random effects model for our analyses. Overall, methotrexate was not associated with an increased risk of total adverse respiratory events compared with comparator agents (relative risk 1.03, 95% confidence interval 0.90 to 1.17, I^2^=0%, fig 2[](#fig2){ref-type="fig"}). In addition we found no increased risk in infectious respiratory events (1.02, 0.88 to 1.19, I^2^=0%) nor non-infectious respiratory adverse events (1.07, 0.58 to 1.96, I^2^=0%) (see supplementary figures 1 and 2). No pulmonary deaths occurred. A single case of pneumonitis was reported in a patient treated with methotrexate in one study, but no definitive diagnostic features or additional information were reported.[@ref20]

![**Fig 2** Forest plot of relative risk for total adverse respiratory events for methotrexate compared with comparator agents](conr023287.f2_default){#fig2}

###### 

 Respiratory adverse events reported in individual studies

  Author               Year   Cough   Pneumonitis   Urinary tract infection   Pneumonia   Respiratory tract infection   Asthma   Pulmonary embolism   Nasopharyngitis   Sinusitis   Rhinitis   Rhinorrhoea
  -------------------- ------ ------- ------------- ------------------------- ----------- ----------------------------- -------- -------------------- ----------------- ----------- ---------- -------------
  Feagan et al^20^     2014   15      1             ---                       ---         55                            ---      1                    ---               11          ---        ---
  Gottlieb et al^21^   2012   ---     ---           32                        1           ---                           1        ---                  49                ---         ---        ---
  Kingsley et al^22^   2012   ---     ---           ---                       ---         56                            ---      ---                  ---               ---         ---        ---
  Reich et al^23^      2011   21      ---           23                        ---         ---                           ---      ---                  89                ---         14         ---
  Saurat et al^24^     2008   ---     ---           ---                       ---         ---                           ---      ---                  67                ---         11         6
  Feagan et al^25^     2000   ---     ---           20                        ---         1                             ---      ---                  ---               ---         ---        ---
  Feagan et al^26^     1995   ---     ---           31                        1           ---                           ---      ---                  ---               ---         ---        ---

Respiratory adverse events reported for each study for methotrexate and comparator groups combined.

Risk of bias in included studies
--------------------------------

A risk of bias graph, risk of bias summary, and funnel plot suggested a low risk of bias (see supplementary figures 3-5). Three of the studies provided inadequate information to assess the risk of selection bias.

Sensitivity analysis
--------------------

Additional subgroup analyses showed no effect of study size, disease under study, comparator treatment, study drop-out rate, use of folic acid supplementation, or difference between methotrexate naive patients and those who had previously received methotrexate (table 3[](#tbl3){ref-type="table"}). Two additional studies with fewer than 50 patients were identified; they reported no additional respiratory adverse events and their inclusion did not change the results of the analyses (relative risk 1.03, 95% confidence interval 0.90 to 1.17, I^2^=0%) (see supplementary figure 6).

###### 

 Sensitivity analysis for total respiratory adverse events

  Outcome                              No of studies   No of participants   Relative risk (95% CI)\*
  ------------------------------------ --------------- -------------------- --------------------------
  Study size:                                                               
   \<250 patients                      4               564                  1.10 (0.90 to 1.35)
   ≥250 patients                       3               1066                 0.97 (0.81 to 1.16)
  Disease:                                                                  
   Psoriatic arthritis                 1               221                  1.27 (0.81 to 2.01)
   Psoriasis                           3               1066                 0.97 (0.81 to 1.16)
   Inflammatory bowel disease          3               343                  1.07 (0.85 to 1.34)
  Comparator:                                                               
   Placebo                             6\*             1205                 1.07 (0.90 to 1.26)
   Active comparator                   2\*             534                  0.94 (0.76 to 1.15)
  Folic acid use:                                                           
   Documented                          4               935                  1.01 (0.87 to 1.17)
   None or unclear                     3               695                  1.09 (0.80 to 1.49)
  Methotrexate naïve:                                                       
   Yes                                 3               809                  0.98 (0.80 to 1.20)
   No                                  4               821                  1.08 (0.89 to 1.32)
  Study drop-out rate:                                                      
   ≥30%                                3               614                  1.02 (0.83 to 1.25)
   \<30%                               4               1016                 1.03 (0.86 to 1.23)
  Inclusion of studies \<50 patients   9               1691                 1.03 (0.90 to 1.17)

\*One study contained placebo and active comparator arms, these have been analysed separately for subgroup analysis.

Discussion
==========

In this study we did not find an increase in the risk of pulmonary adverse events among patients treated with methotrexate for psoriasis, psoriatic arthritis, or inflammatory bowel disease. Although methotrexate is reported to cause lung disease, we did not find an increase in the risk of infectious or non-infectious lung disease. These results support the findings of a previous study among patients with rheumatoid arthritis, showing that the risk of non-infectious lung disease is rare, if it exists at all.[@ref17]

Comparison with other studies
-----------------------------

Studies of respiratory adverse events in rheumatoid arthritis are confounded by the propensity for patients to develop pulmonary complications of their underlying disease, including interstitial lung disease, pleural effusions, pulmonary nodules, and infections.[@ref12] [@ref13] While cases of interstitial lung disease in psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis have been reported, these are uncommon.[@ref20] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] Some occurred in patients who were not receiving methotrexate at the onset of their lung disease,[@ref27] [@ref32] [@ref33] whereas others were reported as being due to methotrexate or leflunomide, or both.[@ref20] [@ref28] [@ref29] [@ref30] [@ref31] The inclusion of only double blind randomised controlled trials reduces the potential ascertainment bias resulting from the existing perception that methotrexate causes interstitial lung disease. A single case of pneumonitis due to methotrexate was reported in one paper without further details as to how this conclusion was reached. Our study has a large number of patients who used methotrexate, and the lack of other cases suggests this could also be a chance occurrence.

Interestingly methotrexate did not seem to increase the risk of infectious respiratory events in this study. Methotrexate suppresses the immune system, increasing the risk of infections, and all three diseases have an increased propensity to develop infections, related to both the underlying disease process and immunosuppressive treatment.[@ref34] [@ref35] We did not find this to be the case in our current study, in contrast with a study among patients with rheumatoid arthritis.[@ref17] Most studies included used placebo comparators, reducing the risk that an increased risk of respiratory adverse events in methotrexate treated patients would be masked by a corresponding increase in the comparator group.

Limitations of this study
-------------------------

Our study has some important limitations. Randomised controlled trials have high internal validity but may lack generalisability and are often of shorter duration than observational studies.[@ref36] The generalisation of our results to all patient populations is limited by the inclusion and exclusion criteria of the original randomised controlled trials. Their relevance for other patient populations, especially those with important comorbidities or other diseases, warrants due consideration. Rare events require large patient numbers for conclusive evidence. While we have attempted to tackle this problem with our current study, the number of high quality studies in the final analysis was small, a trade-off between quality and power. Robust analyses of observational patient registries would complement our findings and better deal with some of these issues, although the lack of blinding and perceptions of methotrexate and lung disease would be of some concern.[@ref36] [@ref37] Under-reporting of unexpected outcomes or adverse events is possible, and there were differences between studies in both the terminology and the frequency of respiratory events reported. Detailed information on all respiratory events was not available from all publications, and we did not have access to the unpublished data. Included studies were of relatively short duration, ranging from 16 to 52 weeks; however, reports suggest methotrexate related interstitial lung disease may develop at any time during treatment and occurs in 48% of affected patients within 32 weeks of starting methotrexate.[@ref14] A relatively low number of studies met our inclusion criteria, but these strict criteria enabled us to focus on large scale high quality studies to minimise bias.

Conclusions and policy implications
-----------------------------------

Our study has important clinical implications. Concern among doctors and patients over the potential side effects of methotrexate has led to an ongoing reluctance to initiate or continue an effective drug in situations where it is clinically indicated.[@ref1] [@ref2] [@ref3] Interstitial lung disease is one of the most feared complications of methotrexate treatment, with a reported mortality of 17%.[@ref14] Guidelines for the use of methotrexate recommend treatment cessation when pulmonary symptoms occur, and in some instances not restarting it.[@ref1] [@ref2] This is problematic because methotrexate is often effective, safe, and much cheaper than many alternative treatments. In the current study we found no increased risk of lung disease in methotrexate treated patients with psoriasis, psoriatic arthritis, or inflammatory bowel disease. These findings, coupled with those of a previous study in rheumatoid arthritis, suggest that methotrexate related lung disease is rare, if it exists at all.

In conclusion the results of our meta-analysis found no significant increase in respiratory adverse events in patients with psoriasis, psoriatic arthritis, or inflammatory bowel disease prescribed methotrexate. We cannot exclude a rare but important increase in pulmonary adverse events because of the limitations outlined. Our findings have important implications for methotrexate use in clinical practice.

### What is already known on this topic

1.  Numerous case reports and observational studies have suggested a link between methotrexate and pulmonary disease

2.  A recent meta-analysis in rheumatoid arthritis found that methotrexate was associated with an increased risk of infectious but not non-infectious pulmonary disease

### What this study adds

1.  Methotrexate did not increase the risk of respiratory adverse events in the diseases studies

2.  These results should give doctors and patients the confidence to consider the use of this effective treatment as part of the shared decision making process
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